Magnetic Resonance Imaging Workbench (MRIW) allows analysis of T1-and T2*-weighted dynamic contrast-enhanced magnetic resonance imaging data sets to extract tissue permeability and perfusion characteristics by using standard pharmacokinetic models. Parametric maps are calculated from individual pixel enhancement curves in regions of interest (ROIs) and displayed as color overlays on the anatomic images. User-defined ROIs can be saved to ensure consistency of later reanalysis. Individual parametric maps are visualized together with user-selected parameter time-series plots. The following selections are available: overall ROI enhancement curve and fit, histogram, and individual pixel enhancement curve and fit. Summary data (transfer constant, leakage space, rate constant, integrated area under the gadolinium curve after 60 seconds, relative blood volume, relative blood flow, and mean transit time) may be exported to permanent storage along with per-pixel results for statistical analysis. Numerical values for parameters are displayed below the plot for easy reference. The dynamic range of plots and parametric map overlays is interactively adjustable. Viewing individual enhancement curves and parametric maps allows radiologists to investigate the heterogeneity of contrast agent kinetics for lesion characterization and to scrutinize serial changes in response to therapy. MRIW is written in IDL, enabling it to be used on a variety of computer systems. 
Introduction
Angiogenesis is a complex process critical to the growth and metastasis of malignant tumors. Tumor growth beyond 1-2 mm in solid tissues cannot occur without vascular support (1) . Experiments in transgenic animal tumor models have shown that progression from an in situ cancer to an invasive cancer is accompanied by the onset of angiogenesis (2) . There are a number of clinical examples where vascularization has been related to tumor progression (eg, in the change from breast ductal carcinoma in situ to invasive cancer) (3, 4) . Patient prognosis is related to angiogenesis, and the degree of angiogenic activity has been shown to be an important prognostic factor for overall survival that is independent of other known prognostic variables, including stage, grade, and lymph node status, in a number of cancer types (5) . In addition, vascular access is essential for a tumor to be able to metastasize to distant sites (2) .
Current methods of assessing angiogenesis can be considered as either direct or indirect. The most frequently used direct method is microvessel density counting after immunostaining with panendothelial cell antibodies (6) . Microvessel density counting usually requires tumor tissue from surgical specimens and is unable to provide information on the functional state of the vasculature. More recently, indirect biomarkers of angiogenesis such as the blood level of angiogenic factors and imaging methods have been used. Advantages of indirect methods are that they are noninvasive, can be performed with the tumor in situ, and may be used to monitor response to treatment. Indirect techniques are quantitative, and in the case of imaging, the functional status of the vasculature can be assessed. It is important to note that implanted tumor xenograft data show that there is a discrepancy between perfused and visible microvessels: A variable 20%-85% of microvessels are perfused at any given time; this results in a difference between histologic and functional vascular density (7) .
Dynamic contrast-enhanced magnetic resonance (MR) imaging following the administration of low molecular weight contrast media (Ͻ1 kDa) is the most popular imaging method for evaluating human tumor vascular function in situ (8) . Data reflecting tissue perfusion, microvessel permeability surface area product, and extracellular leakage space can be obtained, depending on the technique used. Insights into these physiologic processes are obtained qualitatively by characterizing kinetic enhancement curves or quantitatively by applying complex compartmental modeling techniques. Advantages of adopting a quantitative approach include derivation of kinetic parameters that are manufacturer and measurement sequence independent, providing pathophysiologic insights into tissue contrast agent kinetic behavior, and the ability to compare parameters acquired serially in the same patient or to compare data obtained from different imaging centers. Therefore, quantitative dynamic contrast-enhanced MR imaging techniques are preferred for antiangiogenesis and antivascular clinical trials (9) .
In this article, we present cross-platform software for analysis of dynamic contrast-enhanced MR imaging data that yields functional parameters for tissue and allows exploration of these results. Specific topics discussed are contrast agent kinetics, contrast agent concentration, functional description, and clinical applications.
TAKE-HOME POINTS
Ⅲ Functional properties of tumor tissue can be measured with dynamic contrast-enhanced MR imaging.
Ⅲ Quantitative contrast agent kinetic information can be derived from suitable dynamic contrast-enhanced MR imaging data.
Ⅲ Software provides interactive display and analysis of kinetic data from dynamic contrast-enhanced MR imaging.
Ⅲ Software has clinical utility in problem solving for treatment of oncology patients.
Contrast Agent Kinetics
Dynamic contrast-enhanced MR imaging allows distinction of malignant tissue from benign and normal tissues by exploiting differences in contrast agent behavior in their respective microcirculations. When a bolus of paramagnetic, low molecular weight contrast agent passes through a capillary bed, it is transiently confined within the vascular space. Blood volume (BV) and blood flow (BF) are terms that can be derived from the "first pass" of the contrast medium. The mean transit time (MTT) is the average time the contrast agent takes to pass through the tissue being studied. These variables are related by the central volume theorem equation (BF ϭ BV/MTT). A number of conditions of the central volume theorem cannot be met in biologic tissues. For example, injection time is not instantaneous and the arterial input function is not typically measured; as a result, the estimates for these parameters are usually semiquantitative or "relative" (rBV and rBF).
The "first pass" describes the initial passage of the bolus of contrast medium and lasts for a few cardiac cycles. In most tissues except the brain, testes, and retina, the contrast agent rapidly passes into the extravascular-extracellular space (EES) (also called the leakage space [v e ]) at a rate determined by the permeability of the microvessels and their surface area and by blood flow. In tumors, typically 12%-45% of the contrast medium leaks into the EES during the first pass (10) . The transfer constant (K trans ) describes the transendothelial transport of low molecular weight contrast medium from the vascular space to the interstitial space.
Four major factors determine the behavior of low molecular weight contrast media in tissues during the first few minutes after injection. These are the characteristics of the bolus and vascular delivery, the blood perfusion, the transport of contrast agent across vessel walls, and the diffusion of contrast medium in the interstitial space. If the delivery of the contrast medium to a tissue is insufficient (flow-limited situations or where vascular permeability is greater than inflow), then blood perfusion will be the dominant factor determining tissue enhancement and K trans approximates to tissue blood flow per unit volume (11) ; this condition is commonly found in extracranial tumors due to high microvessel permeability. If tissue perfusion is sufficient and transport out of the vasculature does not deplete intravascular contrast medium concentration (non-flow limited or permeability limited), then transport across the vessel wall is the major factor that determines tissue enhancement (K trans then approximates to the permeability surface area product). The latter circumstance occurs in areas of radiation fibrosis and in the presence of an intact or partially intact blood-brain barrier but can also occur in extracranial tumors, usually after treatment. The mixed situation occurs most commonly; for low molecular weight gadolinium-containing chelates, there is a tendency for the influence of flow to outweigh that of permeability surface area product in tumors.
As low molecular weight contrast media do not cross cell membranes, the volume of distribution is effectively the EES (v e ). Contrast medium also begins to diffuse into tissue compartments further removed from the vasculature, including areas of necrosis and fibrosis. Over a period typically lasting several minutes to an hour, the contrast agent diffuses back into the vasculature (described by the rate constant or k ep ), from where it is excreted (usually by the kidneys, although some extracellular fluid contrast media have significant hepatic excretion). When capillary permeability is very high, the return of contrast medium is typically rapid, resulting in faster washout as plasma contrast medium concentrations fall.
MR imaging sequences can be designed to be sensitive to the vascular phase of contrast medium delivery (so-called susceptibility-weighted or T2*-weighted dynamic contrast-enhanced MR imaging, which reflects tissue perfusion and blood volume) (12, 13) . Alternatively, MR imaging sequences can be designed to be sensitive to the presence of contrast medium in the EES and thus reflect microvessel perfusion, permeability, and extracellular leakage space (relaxivity-weighted or T1-weighted dynamic contrast-enhanced MR imaging). These two dynamic contrast-enhanced MR imaging methods are compared in Table 1 ; both can be analyzed by using the Magnetic Resonance Imaging Workbench (MRIW) software, whose functional description is given later in this article. By using the capabilities of this software, it is possible to become familiar with the steps for quantifying contrast agent kinetics, to understand the pathophysiologic basis of dynamic contrast-enhanced MR imaging, and to appreciate methods of displaying kinetic data.
Potentially, the software has clinical utility for problem solving in patients with cancer. The problems include aiding in lesion characterization, noninvasive tumor grading, improving the accuracy of tumor staging, directing biopsy sampling, monitoring response to treatment, and determining patient prognosis. A key application is its use as a biomarker for monitoring the angiogenic response to novel antiangiogenic and antivascular therapies during early drug development and thus supporting "go-no go" decisions in drug development programs. In this setting, the MRIW software can also be used for designing clinical trials with efficacy end points by guiding patient (and thereby tumor) selection, identifying the biologically active dose, and being able to predict drug efficacy before the start of largescale trials. Examples of this type of trial are given by Galbraith et al (14) and Morgan et al (15) .
Contrast Agent Concentration
Contrast agents such as gadopentetate dimeglumine affect MR image contrast via two mechanisms. At lower concentrations, such as those found once the agent is distributed throughout the body, the T1 relaxation times of surrounding protons are shortened. This is observed as brightening of signal intensity in a T1-weighted (short echo time, short repetition time) acquisition. At high concentrations, typically during the first pass of a contrast agent bolus through blood vessels, susceptibility gradients are created between the interior and exterior of the blood vessels. This is observed as a decrease in signal intensity in a suitably weighted gradient-echo sequence (ie, long echo time and repetition time). These mechanisms give insight into two different properties: the uptake of contrast agent by the tissue and the perfusion of the tissue. 
Contrast Agent Concentration in Tissue
During measurement of contrast agent uptake, the T1 relaxation rate of a pixel at a given time during the dynamic imaging period is calculated from the ratio of the T1-weighted signal intensity to the proton-density-weighted signal intensity acquired before contrast agent injection. Accurate quantitation of the T1 relaxation times and ultimately the contrast agent concentration requires a prior T1 calibration experiment performed with the proton-density-and T1-weighted measurement sequences. The relationship between the ratio of the proton-density-and T1-weighted signal intensities and the known relaxation times of the test phantoms is usually a single exponential, for the coil and acquisition parameters used. The concentration, C, of contrast agent in the voxel is calculated from the observed changes in T1 relaxation rate from the precontrast value, T1 0 :
where R1 is the longitudinal relaxivity of the contrast agent at the field strength of the MR imaging unit.
Vascular Contrast Agent Concentration
In a perfusion measurement, the change in R2* (⌬R2*) with time caused by the presence of contrast agent can be quantified from a single-echo T2*-weighted dynamic series by using the following formula (16) :
where S 0 is the mean preenhancement signal intensity, S(t) is the signal intensity as a function of time, and TE is the echo time. However, the absolute value of R2* can be calculated from dual-echo data by using the following expression (17) :
Here, ⌬R2* is calculated by offsetting R2* by its mean preenhancement value.
The vascular contrast agent concentration, C v (t), can then be calculated by scaling R2* by the contrast agent relaxivity, r2, in plasma. However, despite being a low molecular weight agent, gadopentetate dimeglumine cannot occupy the entire vascular compartment due to the impermeability of cell membranes of blood cells, so C v (t) must be scaled by the hematocrit fraction, (1 Ϫ Hct), giving the blood plasma concentration, C p (t) (16) :
Unless measured directly from the patient, Hct is assumed to be equal to 0.4, as measured by Just (18) .
Functional Description
MRIW, designed specifically to be cross-platform, is written in IDL (Research Systems, Boulder, Colo) and operates within the freely available IDL Virtual Machine (Research Systems). The software has been tested on the Microsoft Windows (Redmond, Wash) and Solaris (Sun Microsystems, Santa Clara, Calif) platforms. It has an easy-to-use graphical user interface for selection and analysis of dynamic contrast-enhanced MR imaging data. Results are displayed as false color overlays on top of the corresponding anatomic images and may be interactively reviewed on a whole region-of-interest (ROI) basis or a pixelby-pixel basis. The input data for analysis are loaded from image files, which conform to the Digital Imaging and Communications in Medicine (DICOM) medical imaging file format. In the majority of cases, MRIW can automatically determine the correct interval between images but, in the event that it cannot, it permits the user to specify the correct timing interval. Image subtraction may optionally be used when reviewing the dynamic series to assist in suitable placement of ROIs. ROIs may be circular, rectangular, or freehand and are storable. MRIW can perform contrast agent uptake pharmacokinetic analysis on both T1-weighted and first pass bolus modeling of T2*-weighted dynamic contrast-enhanced MR imaging data. The quantitative imaging protocol for T1-weighted imaging uses a proton-density-weighted image acquisition, later used for signal conversion to contrast agent concentration, followed by dynamic T1-weighted image acquisitions of the identical section(s) for a period to allow circulation and uptake of contrast agent (19) . The period of acquisition of dynamic data typically varies from 3 to 8 minutes. The bolus of contrast agent is injected intravenously 30 seconds after the start of the T1-weighted acquisition. The contrast agent is preferably administered at an injection rate of 4 -5 mL/sec by using an automated MR imaging power injector. The T2*-weighted imaging protocol uses a T2*-weighted acquisition and does not require the initial proton-densityweighted acquisition. Injection methodology is the same as for the T1-weighted protocol. A combined acquisition yielding both T1-and T2*-weighted images is also supported; the combined acquisition is a T1-weighted acquisition with the addition of a second echo to provide T2*-weighted images (20) .
Once pharmacokinetic data processing is completed, MRIW provides the ability to view the results, either for the whole ROI or on a pixel-bypixel basis, in the postprocessing window. The average concentration-time curve (CTC) and model fit for the ROI, the histogram of the current functional parameter, or the individual pixel CTC and model fit may be chosen for display. The postprocessing window also allows export of results to formatted text files for more in-depth statistical analysis in other software packages. Histograms, average CTC, and pixel-by-pixel results can be exported in this manner. The currently displayed image and color overlay may be saved to the common portable network graphics (PNG) file format to provide a graphical record of the parameter distribution in the ROI.
Modeling of Contrast Agent Uptake
MRIW enables user-defined calibration curves (single and bi-exponential) to be entered for specific sites and coils. This is typically performed by using a test object with a variety of known T1 relaxation times, such as the Eurospin test object (Diagnostic Sonar, Livingston, West Lothian, Scotland). The interval between calibration measurements depends on the stability of the MR imaging unit being used; they should be performed on a regular basis, particularly after major software or hardware upgrades and after each cryogen fill.
The evolution over time of the contrast agent concentration is modeled by using the model of Tofts and Kermode (21) , which describes the leakage of contrast agent from the blood plasma to the extravascular, extracellular space (EES) through permeable capillary walls. The model provides estimates of physiologic parameters of tissue. The concentration of contrast agent in the blood plasma, C p , is derived theoretically to be a bi-exponential decay (22) :
The two terms in this plasma washout curve correspond to the equilibration of contrast agent between the plasma and extracellular space (fast) and the removal of contrast agent from the plasma by the kidneys (slow). D is the dose of gadopentetate dimeglumine in millimoles per kilogram of body weight. The fast component is represented by a 1 and m 1 , while a 2 and m 2 represent the slow component. By using this plasma curve, the equation for contrast agent concentration in the tumor tissue is obtained:
where k ep ϭ K trans /v e and a 1 , a 2 , m 1 , and m 2 are the parameters of the plasma curve. In the nomenclature reported by Tofts et al (11) , K trans is the transfer constant describing the leakage of contrast agent from the blood plasma to the EES, v e is the fraction of tissue volume comprising the EES, and k ep is the rate constant describing the return of contrast agent from the EES to blood plasma. As noted earlier, K trans is a measure of the permeability surface area product of the capillary walls in the tissue, although measured values may reflect poor delivery of contrast agent in perfusion-limited situations.
MRIW provides default parameters for the T1 calibration curve, the plasma washout curve (22) , and the contrast agent relaxivity, but it allows users to enter, save, and load calibrations for their site-specific parameters, plasma curves, and the relaxivity of the contrast agent in use. This flexibility allows MRIW to handle a wide variety of input data in an appropriate way as long as suitable input parameters are provided. Temporal resolutions of between 1 and 15 seconds are typically used for T1-weighted dynamic studies, and the total acquisition time may be between 3 and 8 minutes. Model fitting is performed by using a nonlinear Levenburg-Marquart method.
The pharmacokinetic modeling is performed on a pixel-by-pixel basis within a user-selected ROI. Not all contrast agent behavior in tissue can be accurately represented with a two-compartment pharmacokinetic model. Where a model fit cannot be achieved, the shape of the uptake curve still provides useful information about tissue properties to the radiologist (23, 24) . The modelindependent integrated area under the gadolinium curve (IAUGC) for each pixel is calculated to permit analysis of tumors where the assumptions underlying the models break down or where a model-independent approach is preferred (9, 25) .
Perfusion Modeling
The decrease in signal intensity corresponding to the passage of a bolus of contrast agent is manifested as a peak or series of peaks in C p (t), corresponding to the first, second, and subsequent passes of the bolus through local vasculature following circulation through the rest of the body. By fitting a model function such as a gamma variate, ␥(t), to the first-pass peak of C p (t), properties such as relative blood volume (rBV), mean transit time (MTT), and relative blood flow (rBF) can be measured. The gamma variate has the following form (17):
where K, ␣, ␤, and AT are fitted parameters: K is a normalization constant, ␣ and ␤ describe the ascending and descending edges of the first-pass peak, respectively, and AT is the arrival time of the bolus (taken from the midpoint of the bolus injection). AT is estimated by using an algorithm suggested in reference 26. To isolate the first-pass peak, images acquired 30 seconds or more after the arrival time of the bolus are not fitted. A numerical model derived by Thompson (27) is used to estimate suitable starting values for each of the parameters in Equation (7). This model uses the ratio r, which is given by the following formula:
where p is the time to peak and p 1/2 is the time to reach half peak intensity on the ascending slope, both of which can easily be measured from C p (t). ␣, ␤, and K are then given by the following formulas:
and
where C p (p) is the value of C p (t) at t ϭ p. The estimates for K, ␣, ␤, and AT are used as input parameters to the nonlinear model-fitting algorithm used to fit Equation (7) to the ⌬R2* data. According to tracer dilution theory, rBV is the area under the fitted curve, MTT is the full width half maximum of the fitted peak, and, according to the central volume theorem, rBF is the ratio rBV/MTT. However, rBV can be estimated by taking the area under the curve (AUC) of C p (t), using the trapezoidal approximation, over a region corresponding to the first-pass peak. This is taken as t ϭ AT to AT ϩ 30 seconds.
UNFOLD (unaliasing by Fourier-encoding the overlaps using the temporal dimension), described by Madore et al (28) , can be used to reduce the effects of noise and transient image artifacts such as the ghosting caused by flow or motion during Fourier transform imaging. This is implemented in MRIW's processing to improve the quality of the data being input to the fitting procedures to enhance the reliability and quality of the fit. For each pixel, the one-dimensional time series data were Fourier transformed to produce the frequency spectrum of the temporal data. These temporal frequencies were then filtered by using a Fermi filter, as given in Equation (12) :
The frequency, , is normalized such that Ϯ max ϭ Ϯ1. The width and sharpness of the filter can be varied by adjusting the values of the shape parameters E F and kT. The values used are E F ϭ 0.25 and kT ϭ 0.04. We have optimized the filter coefficients to ensure best data modeling.
Clinical Applications
In practice, MRIW hides the complexity of pharmacokinetic modeling behind a user-friendly interface, allowing a clinician to easily interact with the data. Once image data series are selected, along with suitable calibration and timing data, the clinician can choose the ROI for analysis. The clinician may choose to scroll through the images to review where the contrast agent is taken up.
Optionally, this may be performed with subtraction images to further highlight the effects of contrast agent. Figure 1 shows the main window of MRIW after ROI selection and data fitting have been performed on a dual-echo data set that provides both T1-and T2*-weighted images. This gives an overview of the results, which can then be reviewed in more detail by using the postprocessing window. The ROI outline in pale blue clearly demarcates pixels that are inside the ROI. Unlike whole-ROI analysis, pixel-by-pixel analysis of dynamic contrast-enhanced MR imaging data reveals the heterogeneity of kinetic parameter distribution present in the tumor. MRIW allows the clinician to view the parametric map as a color overlay on the anatomic image of the section of interest. When roaming the mouse over the parametric map, the clinician can view the fitted parameters of any pixel. In addition, the contrast agent CTC and the fit are shown in the plot to the right of the image and overlay. Where a pixel CTC cannot be fitted, the CTC only is displayed. Figure 2 shows a skull base meningioma in a 48-year-old man with an individual pixel CTC and fit.
There are many reasons why a pixel CTC might not be fitted. MRIW performs internal consistency checks on results to filter out parameter values that are not physiologically reasonable. The reason for failure is recorded, and it is possible for a user to discover this by exporting the per-pixel results to a text file. Comparing the reason for failure with the pixel CTC it corresponds to, a clinician can learn to recognize characteristic curve shapes that cause modeling failure. MRIW's algorithms have been validated by using simulated data. Documentation and usage information Patient motion is a problem in any dynamic measurement, and dynamic contrast-enhanced MR imaging data are no exception. If an enhancing structure moves within the image to the location of an adjacent nonenhancing structure during a measurement, this will cause that pixel CTC to exhibit enhancing behavior. Naive observation of the pixel CTC alone, without consideration of the motion, would incorrectly identify the pixel as enhancing. MRIW assumes that input data are registered, and thus the clinician must review the data for unacceptable motion. This is best achieved in MRIW during ROI selection, optionally by using the subtraction tool. Once an ROI is selected, the clinician can move backward and forward through the dynamic image set and observe the excursions of structures relative to the ROI outline.
Perfusion information is important in assessing both the viability of a tumor and the blood supply, which carries therapeutic agents to treat the tumor. There is a marked difference in the vasculature of normal tissue and of tumors. Normal vasculature forms an ordered structure with continuous, steady flow from arterial supply to venous drainage. Tumor vasculature is typically chaotic, leaky, and tortuous with uneven flow, pooling of blood, and even flow direction reversal. This difference can be demonstrated with MRIW. Figure 3 shows a well-perfused tumor, the same tumor and section shown in Figure 2 . The first CTC, shown in Figure 3a , is of normal tissue vasculature; a sharp first-pass peak is visible with little or no contrast agent remaining in the tissue after passage. The CTC for tumor tissue vasculature shown in Figure 3b has a long tail, which indicates that contrast agent remains in the tumor tissue after first passage. This is due to a combination of tortuous vessels, leakiness of vascular walls allowing contrast agent to leak into the EES, and blood pooling within the tumor. To prevent this affecting the first-pass modeling of perfusion, MRIW uses only 30 seconds of data after the arrival of the contrast agent in the pixel. Figure 2 . Screens from MRIW show the relative blood flow map for the tumor, the ⌬R2* curve for an individual pixel, and the fitted gamma-variate curve. (a) ⌬R2* curve shows the first pass of contrast agent through the vasculature with no obvious recirculation peak. This result is the expected behavior in a vessel where the blood-brain barrier is intact. (b) ⌬R2* curve selected from the tumor shows considerable retention of contrast agent in the pixel after the first pass. This result is typical of tumor ⌬R2* curves because the vasculature is disordered, tortuous, and leaky, thus leading to the large tail in the curve. MRIW uses the data from the bolus arrival time and the following 30 seconds to perform gamma-variate fitting. This feature prevents the slow washout of contrast agent from affecting the quality of the fit for the first pass.
Accurate quantification of functional parameters of tissue makes it possible to compare different data acquisitions of the same patient on different visits. This enables the clinician to assess changes in functional parameters over the course of treatment. Changes in the functional parameters modeled by MRIW are likely to occur before the gross changes in tumor maximum dimensions that are conventionally used to assess response to treatment.
A summary of the features of MRIW is provided in Table 2 .
Conclusions
MRIW was designed to provide a data processing platform for dynamic contrast-enhanced MR imaging data; the use of the IDL runtime library provides a wide range of application platforms for analysis of dynamic contrast-enhanced MR imaging data. It supports the DICOM 3 image format used by modern imaging units and allows visualization of both permeability information from T1-weighted images and perfusion information from T2*-weighted images. The functional parameters are presented as false color overlays on the anatomic images.
Quantitative maps allow serial measurements of the same subject to assess response of tumors to treatment. Pixel-by-pixel analysis prevents the loss of information inherent when analyzing the ROI as a whole. Heterogeneity of a tumor and changes in the heterogeneity over time are important indicators of tumor physiology and response to therapy. MRIW has been used to analyze data for clinical drug trials to assess the efficacy of the particular treatment (29) and compare dynamic contrast-enhanced MR imaging results with results of histologic assessment (30) . The reproducibility of dynamic contrast-enhanced MR imaging measurements has also been investigated (26, 31 
